IL15 and acute myeloid leukemia: Similarly, studies utilizing iPSC-derived NK cells lacking CISH, a negative regulator of IL-15 signaling, have demonstrated in vivo efficacy in preclinical mouse models of AML that will hopefully lead to phase 1 clinical trials [64].